<clinical_study>
  <!-- This xml conforms to an XML Schema at:
    https://clinicaltrials.gov/ct2/html/images/info/public.xsd -->
  <required_header>
    <download_date>ClinicalTrials.gov processed this data on May 29, 2018</download_date>
    <link_text>Link to the current ClinicalTrials.gov record.</link_text>
    <url>https://clinicaltrials.gov/show/NCT02384317</url>
  </required_header>
  <id_info>
    <org_study_id>CL005_168</org_study_id>
    <nct_id>NCT02384317</nct_id>
  </id_info>
  <brief_title>Open-Label Study to Evaluate Safety and Efficacy of CCX168 in Subjects With Immunoglobulin A Nephropathy on Stable RAAS Blockade</brief_title>
  <official_title>An Open-Label Phase 2 Study to Evaluate the Safety and Efficacy of CCX168 in Subjects With Immunoglobulin A Nephropathy on Stable RAAS Blockade</official_title>
  <sponsors>
    <lead_sponsor>
      <agency>ChemoCentryx</agency>
      <agency_class>Industry</agency_class>
    </lead_sponsor>
  </sponsors>
  <source>ChemoCentryx</source>
  <oversight_info>
    <has_dmc>No</has_dmc>
  </oversight_info>
  <brief_summary>
    <textblock>
      This is a pilot study to test safety, tolerability, and efficacy of CCX168 in reducing
      proteinuria in patients with Immunoglobulin A nephropathy and persistent proteinuria despite
      supportive therapy with a maximally tolerated RAAS blocker.
    </textblock>
  </brief_summary>
  <overall_status>Completed</overall_status>
  <start_date>February 2015</start_date>
  <completion_date type="Actual">December 2016</completion_date>
  <primary_completion_date type="Actual">September 2016</primary_completion_date>
  <phase>Phase 2</phase>
  <study_type>Interventional</study_type>
  <has_expanded_access>No</has_expanded_access>
  <study_design_info>
    <intervention_model>Single Group Assignment</intervention_model>
    <primary_purpose>Treatment</primary_purpose>
    <masking>None (Open Label)</masking>
  </study_design_info>
  <primary_outcome>
    <measure>Safety of CCX168 in subjects with Immunoglobulin A nephropathy measured by number of patients with adverse events</measure>
    <time_frame>169 days</time_frame>
    <description>Safety assessments in all patients include number with adverse events</description>
  </primary_outcome>
  <secondary_outcome>
    <measure>Evaluate the efficacy of CCX168 based on numbers of patients with improvement in proteinuria</measure>
    <time_frame>169 days</time_frame>
    <description>improvement in proteinuria</description>
  </secondary_outcome>
  <number_of_arms>1</number_of_arms>
  <enrollment type="Actual">5</enrollment>
  <condition>Immunoglobulin A Nephropathy</condition>
  <arm_group>
    <arm_group_label>CCX168</arm_group_label>
    <arm_group_type>Experimental</arm_group_type>
    <description>BID for 84 days</description>
  </arm_group>
  <intervention>
    <intervention_type>Drug</intervention_type>
    <intervention_name>CCX168</intervention_name>
    <description>BID for 84 days</description>
    <arm_group_label>CCX168</arm_group_label>
  </intervention>
  <eligibility>
    <criteria>
      <textblock>
        Key Inclusion Criteria:

          -  Diagnosis of Immunoglobulin A nephropathy

          -  estimated glomerular filtration rate &gt;60 mL/min/1.73 m2

          -  Proteinuria (first morning urinary protein:creatinine ratio &gt;1g/g creatinine)

        Key Exclusion Criteria:

          -  Severe renal disease

          -  Pregnant or nursing

          -  Proteinuria &gt;8g/g creatinine or &gt;8g/day

          -  Systemic manifestations of Henoch-Schonlein purpura within 2 years prior

          -  Patients with Immunoglobulin A nephropathy deemed secondary to underlying disease

          -  Biopsy reported severe crescentic Immunoglobulin A nephropathy

          -  History of treatment with glucocorticoids, cyclophosphamide, azathioprine,
             mycophenolate mofetil, or any biologic immunomodulatory agent with 24 weeks prior

          -  History of clinically significant cardiac conditions

          -  History of cancer within 5 years prior

          -  Any infection requiring antibiotic treatment that has not cleared prior to study start
      </textblock>
    </criteria>
    <gender>All</gender>
    <minimum_age>18 Years</minimum_age>
    <maximum_age>N/A</maximum_age>
    <healthy_volunteers>No</healthy_volunteers>
  </eligibility>
  <overall_official>
    <last_name>Pirow Bekker, MD, PhD</last_name>
    <role>Study Director</role>
    <affiliation>ChemoCentryx</affiliation>
  </overall_official>
  <location>
    <facility>
      <address>
        <city>Palo Alto</city>
        <state>California</state>
        <country>United States</country>
      </address>
    </facility>
  </location>
  <location>
    <facility>
      <address>
        <city>San Francisco</city>
        <state>California</state>
        <country>United States</country>
      </address>
    </facility>
  </location>
  <location>
    <facility>
      <address>
        <city>Reno</city>
        <state>Nevada</state>
        <country>United States</country>
      </address>
    </facility>
  </location>
  <location>
    <facility>
      <address>
        <city>Chapel Hill</city>
        <state>North Carolina</state>
        <country>United States</country>
      </address>
    </facility>
  </location>
  <location>
    <facility>
      <address>
        <city>Columbus</city>
        <state>Ohio</state>
        <country>United States</country>
      </address>
    </facility>
  </location>
  <location>
    <facility>
      <address>
        <city>Stockholm</city>
        <country>Sweden</country>
      </address>
    </facility>
  </location>
  <location_countries>
    <country>Sweden</country>
    <country>United States</country>
  </location_countries>
  <verification_date>December 2016</verification_date>
  <!-- For several months we've had both old and new date name tags                             -->
  <!-- Now, the old date names have been dropped.                                               -->
  <!-- The new date name replacements are:                                                      -->
  <!--     OLD (gone)                                        NEW (in use)                       -->
  <!--   lastchanged_date                         becomes   last_update_submitted               -->
  <!--   firstreceived_date                       becomes   study_first_submitted               -->
  <!--   firstreceived_results_date               becomes   results_first_submitted             -->
  <!--   firstreceived_results_disposition_date   becomes   disposition_first_submitted         -->
  <study_first_submitted>February 11, 2015</study_first_submitted>
  <study_first_submitted_qc>March 4, 2015</study_first_submitted_qc>
  <study_first_posted type="Estimate">March 10, 2015</study_first_posted>
  <last_update_submitted>December 19, 2016</last_update_submitted>
  <last_update_submitted_qc>December 19, 2016</last_update_submitted_qc>
  <last_update_posted type="Estimate">December 20, 2016</last_update_posted>
  <responsible_party>
    <responsible_party_type>Sponsor</responsible_party_type>
  </responsible_party>
  <condition_browse>
    <!-- CAUTION:  The following MeSH terms are assigned with an imperfect algorithm            -->
    <mesh_term>Kidney Diseases</mesh_term>
    <mesh_term>Glomerulonephritis, IGA</mesh_term>
  </condition_browse>
  <intervention_browse>
    <!-- CAUTION:  The following MeSH terms are assigned with an imperfect algorithm            -->
    <mesh_term>Immunoglobulins</mesh_term>
    <mesh_term>Antibodies</mesh_term>
    <mesh_term>Immunoglobulin A</mesh_term>
  </intervention_browse>
  <!-- Results have not yet been posted for this study                                          -->
</clinical_study>

